Thoracic surgery

Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021

Retrieved on: 
Tuesday, July 6, 2021
Hyperhidrosis, Thoracic surgery, Medical specialties, Health care, Life sciences

BOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in one-on-one investor meetings at the upcoming William Blair Biotech Focus Conference 2021, taking place virtually July 14 - 15.

Key Points: 
  • BOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in one-on-one investor meetings at the upcoming William Blair Biotech Focus Conference 2021, taking place virtually July 14 - 15.
  • Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis.
  • Brickells strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
  • For more information, visit https://www.brickellbio.com .

Dermadry's Anti Sweat Device Secures the Seal of Approval from the American Podiatric Medical Association

Retrieved on: 
Wednesday, June 30, 2021
Branches of biology, Medicine, Anatomy, Hyperhidrosis, Thoracic surgery, American Podiatric Medical Association, Podiatry, Perspiration, Non-contact thermography, Food and Drug Administration

Which is why Dermadry is proud to announce that they have received the Seal of Approval from the American Podiatric Medical Association (APMA) for Dermadry Total.

Key Points: 
  • Which is why Dermadry is proud to announce that they have received the Seal of Approval from the American Podiatric Medical Association (APMA) for Dermadry Total.
  • By giving their Seal of Approval to Dermadry Total, APMA recognizes the effectiveness of the product in the treatment of excessive sweating.
  • Dermadry's APMA Seal of Approval arrives just weeks after receiving the CE marking for the Europe market.
  • They manufacture an FDA cleared iontophoresis device that treats hyperhidrosis , a medical condition characterized by excessive sweating.

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidro

Retrieved on: 
Tuesday, June 29, 2021
Health sciences, Health, Clinical research, Design of experiments, Pharmaceutical industry, Hyperhidrosis, Thoracic surgery, Clinical trial, Brickell, Cardigan, Ceredigion

This is truly an exciting time for the Brickell team, as we have now completed enrollment in both of our Phase 3 pivotal clinical studies of sofpironium bromide gel, 15%.

Key Points: 
  • This is truly an exciting time for the Brickell team, as we have now completed enrollment in both of our Phase 3 pivotal clinical studies of sofpironium bromide gel, 15%.
  • We look forward to sharing updates on the progress of the Phase 3 pivotal clinical studies over the coming months.
  • Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

Retrieved on: 
Thursday, June 24, 2021
Clinical research, Health sciences, Health, Medical research, Design of experiments, Hyperhidrosis, Thoracic surgery, Placebo-controlled study, Placebo, Clinical trial

In Japan, 5.33% and 2.79% of the population are estimated to be affected by primary palmar and plantar hyperhidrosis, respectively1.

Key Points: 
  • In Japan, 5.33% and 2.79% of the population are estimated to be affected by primary palmar and plantar hyperhidrosis, respectively1.
  • Depending on the outcome of the Phase 1 study, Kaken and Brickell will determine the next steps, if any, for the development of sofpironium bromide gel in PPH patients in their respective territories.
  • Phase 3 pivotal program for sofpironium bromide gel, 15% which is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Both randomized, double-blinded, placebo-controlled pivotal studies are evaluating sofpironium bromide gel, 15% vs. placebo (1:1 ratio) in approximately 350 subjects (per study) aged nine and older with primary axillary hyperhidrosis.

Howard Shackelford, MD, FACS, FACC, is being recognized by Continental Who's Who

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Surgery, Clinical medicine, Cardiac surgery, Surgical specialties, Cardiothoracic surgery, Thoracic surgery, Cardiothoracic anesthesiology, Rafael Espada

Having garnered 45 years of professional excellence in his field, Dr. Howard Shackelford is a board-certified and respected Cardiothoracic Surgeon.

Key Points: 
  • Having garnered 45 years of professional excellence in his field, Dr. Howard Shackelford is a board-certified and respected Cardiothoracic Surgeon.
  • Dr. Shackelford is chairman of the Wheeling Hospital's Cardiac, Thoracic, and Vascular Services in his current capacity.
  • As a surgeon, he devotes his work to providing the highest standard of general, vascular, and trauma surgeries for his patients.
  • With a commitment to excellence, Dr. Shackelford is board-certified by the American Board of Surgery and the American Board of Thoracic Surgery.

AtriCure Names Two New Members to the Board of Directors

Retrieved on: 
Tuesday, June 15, 2021
Hospitals, Health, Cardiology, Medical devices, Medical specialties, Surgery, Clinical medicine, Surgical specialties, Cardiac surgery, Cardiothoracic surgery, Thoracic surgery, Atrial fibrillation

Going forward she has responsibility for the companys worldwide legal affairs, compliance, and global environmental health and safety.

Key Points: 
  • Going forward she has responsibility for the companys worldwide legal affairs, compliance, and global environmental health and safety.
  • Im looking forward to joining the board of AtriCure and working with Mike and the rest of the management team to further the companys mission, said Ms. Telman.
  • I am thrilled that Deb and Maggie have agreed to join the AtriCure Board of Directors, said Michael Carrel, President and Chief Executive Officer.
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

Hyperhidrosis Treatment Market Report 2021: Global Industry Analysis, Trends, Market Size, and Forecasts 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 11, 2021
Biotechnology, Pharmaceutical, Health, Hyperhidrosis, Thoracic surgery, Forecasting

The "Hyperhidrosis Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyperhidrosis Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global hyperhidrosis treatment market to grow with a CAGR of 5.00% over the forecast period from 2020-2026.
  • The report on the global hyperhidrosis treatment market provides qualitative and quantitative analysis for the period from 2018 to 2026.
  • The report on hyperhidrosis treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global hyperhidrosis treatment market over the period of 2018 to 2026.

Heart & Vascular Center at Valley View Offers Open Heart Surgery and New Cardiothoracic Procedures, Under the Leadership of Cardiothoracic Surgeon Stephen Jones, MD

Retrieved on: 
Wednesday, June 9, 2021
Medical specialties, Surgery, Clinical medicine, Cardiac surgery, Cardiothoracic surgery, Thoracic surgery, Cardiothoracic anesthesiology

Stephen Jones, MDhas begun an open heart surgical program at Valley View with 10 open heart procedures performed to date.

Key Points: 
  • Stephen Jones, MDhas begun an open heart surgical program at Valley View with 10 open heart procedures performed to date.
  • Valley View now offers a wide range of treatments and the most experienced cardiothoracic surgeon on Colorado's Western Slope.
  • Dr. Jones joins the Heart & Vascular Center from St. Alphonsus Regional Medical Center in Boise, Idaho, where he was the chief of Cardiothoracic Surgery for 10 years.
  • "We are very pleased to welcome Dr. Jones to Valley View," said Brian Murphy, MD, CEO of Valley View.

Vanessa Gibson, MD, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Surgery, Thoracic surgery, Clinical medicine, Cardiac surgery, Cardiothoracic surgery, Society of Thoracic Surgeons

LYNBROOK, N.Y., June 8, 2021 /PRNewswire/ -- Vanessa Gibson, MD is being recognized by Continental Who's Who as a Top Thoracic Surgery Specialist for her exemplary service to the healthcare community.

Key Points: 
  • LYNBROOK, N.Y., June 8, 2021 /PRNewswire/ -- Vanessa Gibson, MD is being recognized by Continental Who's Who as a Top Thoracic Surgery Specialist for her exemplary service to the healthcare community.
  • As a Thoracic Surgery Specialist at Long Island Thoracic Surgery PC, Dr. Gibson provides personalized care to patients with chest and lung issues.
  • An active member of her field, Dr. Gibson is a member of the Society of Thoracic Surgeons.
  • As a testament to her professional excellence, Dr. Gibson was recognized as a CMS Stage 1 EHR in 2012.

Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Surgery, Anatomy, Cardiac surgery, Thoracic surgery, Mitral valve, Valvular heart disease, Heart valve, Cardiothoracic surgery, Mitral valve replacement, Charles P. Bailey, EPYGON, AFFLUENT

Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.

Key Points: 
  • Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.
  • Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency.
  • Preclinical in vivo results published in The Annals of Thoracic Surgery confirm the Epygon mitral valve ability to adapt to the heart while restoring the native-like blood flow.
  • The company today announced the publication of preclinical data of its mitral valve Epygon in the renowned Annals of Thoracic Surgery on "Novel transcatheter mitral prosthesis designed to preserve physiological ventricular flow dynamics" ( https://www.annalsthoracicsurgery.org/article/S0003-4975(21)00646-9/fulltext ).